Product Description
Mechanisms of Action: FGFR Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Kaken Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Diabetic Foot|Periodontal Attachment Loss|Alveolar Bone Loss|Periodontitis
Phase 2: Periodontitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| KCB-1D-02 | P2 |
Completed |
Periodontitis |
2007-07-01 |
2019-03-21 |
Treatments |
|
| JapicCTI-050033 | P2 |
Unknown |
Periodontitis |
None |
|||
| The TRAfermin in Neuropathic diabetic foot ulcer Study - southern Europe. The TRANS-North study | P3 |
Completed |
Diabetic Foot |
2013-02-06 |
2022-03-13 |
Treatments |
|
| The TRAfermin in Neuropathic diabetic foot ulcer Study - northern Europe. The TRANS-North study | P3 |
Terminated |
Diabetic Foot |
2012-09-30 |
2022-03-13 |
Treatments |
|
| TRANS-North | P3 |
Completed |
Diabetic Foot |
2012-05-01 |
2019-03-19 |
Treatments |
|
| TRANS-South | P3 |
Completed |
Diabetic Foot |
2012-03-01 |
2019-03-19 |
Treatments |
|
| KCB-1D-04 | P3 |
Completed |
Periodontitis |
2010-03-01 |
2019-03-19 |
Treatments |
|
| Trafermin | P3 |
Completed |
Periodontitis|Alveolar Bone Loss|Periodontal Attachment Loss |
2010-03-01 |
2019-03-18 |
Treatments |